Cognition Therapeutics, Inc.
General ticker "CGTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $50.5M (TTM average)
Cognition Therapeutics, Inc. follows the US Stock Market performance with the rate: 41.9%.
Estimated limits based on current volatility of 3.1%: low 1.03$, high 1.09$
Factors to consider:
- Earnings expected soon, date: 2026-03-19 bmo
- Total employees count: 28 (+12.0%) as of 2023
- Top business risk factors: Operational and conduct risks, Economic downturns and volatility, Labor/talent shortage/retention, Regulatory and compliance, Market volatility
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.43$, 1.41$]
- 2025-12-31 to 2026-12-31 estimated range: [0.42$, 1.32$]
Financial Metrics affecting the CGTX estimates:
- Positive: with PPE of -0.8 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -108.26 <= 0.01
- Positive: Investing cash flow per share per price, % of -0.02 > -0.63
- Positive: Inventory ratio change, % of 0 <= 0.80
- Positive: 42.68 < Shareholder equity ratio, % of 62.02 <= 64.29
Short-term CGTX quotes
Long-term CGTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $43.55MM | $50.72MM | $53.97MM |
| Operating Income | $-43.55MM | $-50.72MM | $-53.97MM |
| Non-Operating Income | $22.19MM | $24.94MM | $20.00MM |
| Interest Expense | $0.03MM | $0.00MM | $0.03MM |
| R&D Expense | $30.32MM | $37.20MM | $41.68MM |
| Income(Loss) | $-21.36MM | $-25.79MM | $-33.97MM |
| Profit(Loss)* | $-21.40MM | $-25.79MM | $-33.97MM |
| Stockholders Equity | $40.25MM | $24.47MM | $18.75MM |
| Assets | $50.42MM | $35.16MM | $30.23MM |
| Operating Cash Flow | $-18.53MM | $-16.02MM | $-28.47MM |
| Capital expenditure | $0.17MM | $0.15MM | $0.00MM |
| Investing Cash Flow | $-0.17MM | $-0.15MM | $-0.00MM |
| Financing Cash Flow | $5.55MM | $4.52MM | $23.57MM |
| Earnings Per Share** | $-0.74 | $-0.86 | $-0.86 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.